The Under Secretary for Health evaluates the need for conducting research on the use of ketamine and esketamine for treatment-resistant depression including the comparative efficacy of ketamine and esketamine, the effect of route of administration, therapeutic dose range, mechanism of action, and efficacy and safety of long-term treatment, and initiates research efforts as indicated.
Questioned Costs
$0
Funds for Better Use
$0
Recommendation Status
Closed
Source UUID
20-03359-220-2
Recommendation Number
2
Significant Recommendation
Yes